William Blair analyst Lachlan Hanbury Brown has maintained their bullish stance on APLS stock, giving a Buy rating on July 1.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Lachlan Hanbury Brown has given his Buy rating due to a combination of factors related to Apellis Pharmaceuticals’ market position and growth potential. The analyst notes the company’s steady increase in market share for its product, Syfovre, which has been gaining traction over several months. This trend suggests a sustainable growth trajectory rather than a temporary spike, indicating strong long-term prospects for the company.
Furthermore, despite competitive pressures from Astellas’ Izervay, Apellis has demonstrated resilience and the ability to capture new patient share. The analyst also highlights the broader market potential, with expectations of significant growth in the GA market and a substantial number of patients being treated with complement inhibitors by 2027. These factors collectively support the Buy rating, reflecting confidence in Apellis’s ability to capitalize on market opportunities and deliver sustained growth.
In another report released on July 1, TD Cowen also maintained a Buy rating on the stock with a $50.00 price target.